Global Polycystic Ovarian Syndrome Treatment Market Size, Share, Forecast Report, 2020-2027

The global polycystic ovarian syndrome treatment market size was valued at $2,902 million in 2018, and is projected to reach $4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.

Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, various medications are used to regulate menstrual cycle and to manage symptoms of PCOS.

Increase in prevalence of PCOS, rise in awareness among patient population with increase in adoption of combination therapy drives the polycystic ovarian syndrome treatment market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medications, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics, and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth. Furthermore, untapped potential offered by developing economies present lucrative opportunities for the growth of the polycystic ovarian syndrome treatment market during the forecast period. However, lack of specific treatment for PCOS disorder is expected to restrain the growth of the market. The rise in prevalence of PCOS is expected to augment the demand for PCOS treatment medications. For instance, Centers for Disease Control and Prevention estimated that PCOS is one of the most common causes of female infertility, affecting 6 to 12% (as many as 5 million) of the American women of reproductive age. The number of PCOS patients is increasing due to the growing incidences of co-morbid conditions such as diabetes and obesity.

Polycystic Ovarian Syndrome Treatment Market Segmentation

The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

By drug class, the market is categorized into insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. Presently, the insulin sensitizing agent segment is the major revenue contributing segment in 2018 and is estimated to show a significant market growth during the forecast period due to higher adoption of insulin sensitizing agents as the first line treatment for the management of PCOS.
According to distribution channel, the polycystic ovarian syndrome treatment market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment is anticipated to depict a significant growth during the forecast period, due to rise in preference for online purchasing of drugs over the traditional methods, increase in awareness of online providers, and rise in number of internet users.
Snapshot of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market

Asia-Pacific presents lucrative opportunities for the key players operating in the polycystic ovarian syndrome treatment market, owing to the growth in awareness about polycystic ovarian syndrome treatment, rise in adoption of polycystic ovarian syndrome treatment products will drive the market growth. Moreover, improvement in healthcare infrastructure, rise in number of target population, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contributes to the market growth. In addition, factors such as surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, high population base, and high disposable incomes are also expected to drive the growth of the polycystic ovarian syndrome treatment market in Asia-Pacific.
The key players profiled in this report include Allergan plc., AstraZeneca plc., Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries.

Key Benefits for Stakeholders:

• The study provides an in-depth analysis along with the current polycystic ovarian syndrome treatment market trends and future estimations to elucidate the imminent investment pockets.
• It offers polycystic ovarian syndrome treatment market analysis from 2018 to 2026, which is expected to enable stakeholders to capitalize the prevailing opportunities in the market.
• A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global polycystic ovarian syndrome treatment market growth.

Key Market Segments:

By Drug Class 

• Insulin Sensitizing Agent
• Oral Contraceptive
• Antiandrogens
• Anti-Obesity Drugs
• Others

By Distribution Channel 

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA